A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Registrational
- Sponsors Novartis; Novartis Pharmaceuticals
- 06 Jun 2018 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 This study is completed in Portugal (End date: 2017-12-27).
- 06 Mar 2018 This trial has been completed in Poland (End date: 2017-12-27).